Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation.

Molecular cancer therapeutics - 1 Dec 2010

Rho Jin Kyung, Choi Yun Jung, Jeon Byung-Suk, Choi Su Jin, Cheon Gi Jeong, Woo Sang-Keun, Kim Hye-Ryoun, Kim Cheol Hyeon, Choi Chang-Min, Lee Jae Cheol

Abstract excerpt

Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) produce an initially dramatic response in lung cancer patients harboring a mutation in the EGFR gene, development of acquired resistance is almost inevitable. A secondary mutation of threonine 790 (T790M) is associate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Down-Regulation
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Erlotinib Hydrochloride

Share to Protein Multimerization

Share to Quinazolines

Share to Tyrosine

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 21159609
DOI: 10.1158/1535-7163.MCT-10-0625

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21159609-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation.PMID 21159609Read ↗

EGFR-TKIs resistance via EGFR-independent signaling pathways.Semantic proximity Read ↗

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation.Semantic proximity Read ↗

Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells.Semantic proximity Read ↗

Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.Semantic proximity Read ↗

Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.Semantic proximity Read ↗

244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.Semantic proximity Read ↗

T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.Semantic proximity Read ↗

The miR‑625‑3p/AXL axis induces non‑T790M acquired resistance to EGFR‑TKI via activation of the TGF‑β/Smad pathway and EMT in EGFR‑mutant non‑small cell lung cancer.Semantic proximity Read ↗

[Research Progress on the Combination Therapy of EGFR-TKIs and Metformin in Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer].Semantic proximity Read ↗

AXL up-regulates PD-L1 inducing gefitinib resistance in EGFR mutated NSCLCSemantic proximity Read ↗

Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation.Semantic proximity Read ↗

Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.